Navigation Links
Pain and Intensity Of Post-stroke Spasticity Decreased by Botox Treatment

Final results from a multi-center study shows that repeated treatments of botulinum toxin type A over one year is well tolerated and results in a significant decrease in spasticity, pain frequency and average pain intensity in upper limbs following stroke, according to research from a neurologist at Wake Forest University Baptist Medical Center.

Significant improvements in these outcome measures indicate a better quality of life for post-stroke patients suffering from spasticity-related pain, according to the researchers who presented their findings today at the annual meeting of the American Academy of Neurology in Boston. Spasticity is a disabling condition that leaves the muscles and tendons permanently shortened and inhibits movement.

In the clinical setting, limb stiffness and pain are the most commonly reported symptoms of spasticity following a stroke, and relief of spasticity-related pain is a priority treatment goal for many patients, said Allison Brashear, M.D., professor and chairman of neurology at Wake Forest University Baptist Medical Center and head of the spasticity clinic at Wake Forest Baptist.

Our study shows that treatment with botulinum toxin type A can lessen these disabling symptoms without treatment-limiting side effects, which in turn improves the ability of stroke patients to perform such essential activities of daily living as dressing themselves, maintaining good personal hygiene, and reaching for and grasping everyday objects.

This is the largest long-term study to evaluate repeated treatment with BoNTA for post-stroke spasticity. Brashear and colleagues had reported in 2002 that one-time injections of BoNTA are safe and effective in people with wrist and finger spasticity after a stroke.

About 58 percent of stroke survivors experience post-stroke spasticity, and only 51 percent of those are receiving treatment for that condition, according to the National Stroke A ssociation.

A total of 279 patients were enrolled in the 12-month study of BoNTA to evaluate the efficacy and safety of repeated BoNTA treatments. All study participants received up to five treatments of BoNTA. For the study, the BoNTA injections were given at the elbow, wrist and fingers and/or thumbs flexor of the affected limb to block overactive nerve impulses that trigger excessive muscle contractions. Patients were assessed every six weeks for one year. Patients demonstrated a significant reduction in pain and excessive muscle tone at each follow-up. In addition, average pain intensity was significantly reduced.

Early intervention with effective therapies is absolutely vital to prevent the profound disability that afflicts many stroke patients, said Brashear. Having data to support a safe and effective profile for long-term treatment with BoNTA is significant for patients and caregivers. Many oral anti-spasticity medications are associated with systemic side effects such as sedation, mental confusion, dizziness and muscle weakness, all of which can seriously hinder rehabilitation after a stroke.


'"/>




Related medicine news :

1. Low-Intensity Exercise The Key To Losing More Pounds
2. Good Sleep Habits Could Reduce the Intensity of Migraines
3. Varying Weight Training Intensity Ups Growth Hormone in Women
4. Intensity of Rheumatoid Arthritis Significantly Reduced by Pregnancy
5. Chicken Eaters Have Decreased Risk Of Developing Colon Cancer
6. Asthma Risk Related To Decreased Fruit and Vitamin C consumption
7. Asthma Risk Related To Decreased Fruit and Vitamin C consumption
8. Decreased Vitamin D Intake among Teens Results in Decreased Lung Function
9. Secure Relationship Leads To Decreased Libido In Women
10. New antiperspirant in action - Botox does the difference
11. New Research Has Found Another Use For Botox
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/6/2016)... ... December 06, 2016 , ... TopConsumerReviews.com recently gave a best-in-class 5 star rating ... Scooters give freedom to people who need help getting around. For some, advancing age ... long period of rehabilitation after an illness or accident. There is a wide variety ...
(Date:12/6/2016)... ... December 06, 2016 , ... "Add realistic flares and ... flash, and flare from clip to clip with high quality 4K lens flare footage," ... Jewel contains 44 lens flares filmed on the RED Dragon. Utilizing the Dragon Sensor, ...
(Date:12/5/2016)... ... December 05, 2016 , ... What: Shriners Hospitals for Children, with ... to our patients – using a video monitor and web-enabled camera. Santa visits with ... the Auditorium into a Christmas Wonderland, which is where the video connection to the ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... Surgery, is excited to announce the arrival of the newest Sciton laser in ... the ability to use tunable non-ablative and ablative wavelengths for exceptional results. Outperforming ...
(Date:12/5/2016)... ... December 06, 2016 , ... For many years, ... , both thick and thin. The beauty of the Lithuanian language and ... , In this poetry book, Zubinas lyrically explores all aspects of a living, breathing ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... Dec. 5, 2016   Mallinckrodt Pharmaceuticals (NYSE: ... company, today announced that it received a perfect score ... (CEI), a national benchmarking survey and report on corporate ... transgender (LGBT) workplace equality, administered by the Human Rights ... major U.S. businesses which also earned top marks this ...
(Date:12/5/2016)... , Dec. 5, 2016 Special purpose needles are ... such as fluid and cells from organs or lumps and ... and sizes. The global market for special purpose needles is ... In terms of revenue, the global special purpose needles market ... the forecast period (2016–2026) and is expected to be valued ...
(Date:12/5/2016)...   Lexicon Pharmaceuticals, Inc. (Nasdaq: ... 2 clinical study of sotagliflozin, a dual SGLT1 and ... the leading global organization funding type 1 diabetes research. ... trial, which randomized a total of 87 patients, was ... dose of sotagliflozin compared to a placebo control in ...
Breaking Medicine Technology: